GLP1R and type 2 diabetes mellitus: Given their glucose lowering and cardioprotective effect, GLP-1 receptor agonists (GLP-1 RAs) can represent additional or alternative first-line therapeutic agents for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or at high risk of CV/renal complications [79].